Skip to main content
Equibles
CABA logo

CABA · Cabaletta Bio, Inc. · Metrics

Track CABA — free

Use CABA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CABA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.33 -0.12 (-8.28%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Nov 5, 2026

The latest filing states the doubt was alleviated.

“As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we had previously identified conditions that raised substantial doubt about our ability to continue as a going concern. During the quarter ended September 30, 2026, we raised additional funds through the exercise of common stock warrants for proceeds of $115.0 million and sold 1.9 million shares pursuant to the 2025 ATM Program for net proceeds of $6.0 million. As a result of these cash raises, the conditions that previously raised substantial doubt are no longer present.”
View the 10-Q filed Nov 5, 2026
Market Cap
$286.91M
Shares
215.72M
Volume · Nov 12 3.73M Avg daily vol (3M) 5.32M

CABA metrics

63 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.33
Market cap
$286.91M

Price action

23 metrics
Price change (1W)
+2.1%
Price change (30D)
-14.2%
Price change (3M)
-49.1%
Price change (6M)
-59.6%
Price change (YTD)
-33.8%
Price change (1Y)
-41.3%
Trailing year
Price change (5Y)
-88.5%
52-week high
$4.15
52-week low
$1.28
Change from 52-week high
-65.1%
Change from 52-week low
+13.3%
Annualized volatility
83.1%
Annualized volatility (3M)
84.2%
Implied volatility (30D)
153.0%
IV rank (1Y)
80.2
IV percentile (1Y)
98.5
Beta
1.8
RSI (14D)
41.2
Price vs SMA 50
-28.1%
Price vs SMA 200
-48.4%
Avg volume (3M)
5.30M
Relative volume
0.7
Average dollar volume
$12.11M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
215.72M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 90.8%
FCF yield
-52.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-60.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-10

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$193.63M
Net income (TTM)
−$189.50M
Trailing 12 months
Diluted EPS (TTM)
$-1.23
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.12

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+82.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-66.7%
Return on assets
-56.3%
Debt / equity
—
Current ratio
6.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$162.51M
Quick ratio
6.5
Interest coverage
-87.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$299.38M
Latest balance sheet
Cash & equivalents
$299.38M
Total assets
$336.49M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$162.16M
Capital expenditures (TTM)
$347,000
R&D (TTM)
$165.12M
SG&A (TTM)
—
Stock compensation (TTM)
$20.28M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
139
13F filer change QoQ
+31
Institutional ownership
75.4%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
42.1%
Private-fund adviser ownership
40.2%
Active holders' share change QoQ
+59.5%
Holder tenure
11.2
Price vs estimated holder cost
-14.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.4%

Short interest

3 metrics
Short interest
17.8%
Latest settlement · 8.2 days to cover
Days to cover
8.2d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1759138 CUSIP 12674W109 13F (30d) 80 filings 71 filers Visit website Investor relations